NCT03954327

Combination Antiretroviral Therapy (cART) for PBC

Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: University of Alberta · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) \& Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

Detailed description

Primary endpoint: Change in mean percentage of alkaline phosphatase (ALP) reduction in cART vs. placebo at 6 and 12 months. Secondary endpoints: 1. Serum biochemistries bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) will be studied as continuous variables. 2. Composite endpoint used for the POISE study \[A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis\]: (i) reduction of ALP to \< 1.67 upper limit of normal, (ii) normalization of bilirubin within upper limit of normal (ULN) and (iii) reduction of ALP by \> 15% at 6 and 12 months. 3. Symptomatic evaluation performed using the PBC-40 to assess five symptom domains relating to fatigue, itch, cognitive symptoms, social and emotional symptoms, and other symptoms. 4. Histological change in grade and stage of PBC using the Nakanuma scoring system for a subgroup of patients undergoing liver biopsy \[liver biopsy not compulsory for study\]. 5. Serial human betaretrovirus measurement in peripheral blood and cellular immune response to viral peptides.

Conditions

• Primary Biliary Cholangitis

Interventions

Type	Name	Description
DRUG	Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)	Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
DRUG	Raltegravir	Raltegravir (RTF) 600 mg two tablets by mouth once per day
DRUG	Placebo Oral Capsule [CEBOCAP]	Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day

Timeline

• Start date: 2021-03-01
• Primary completion: 2022-10-01
• Completion: 2024-01-01
• First posted: 2019-05-17
• Last updated: 2024-02-16

Locations

6 sites across 1 country: Canada